

**NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE**

**Single Technology Appraisal**

**Anifrolumab for treating active autoantibody-positive systemic lupus erythematosus [ID3804]**

**Final stakeholder list**

<b>Consultees</b>	<b>Commentators (no right to submit or appeal)</b>
<p><u>Company</u></p> <ul style="list-style-type: none"> <li>• AstraZeneca (anifrolumab)</li> </ul> <p><u>Patient/carer groups</u></p> <ul style="list-style-type: none"> <li>• Action on Pain</li> <li>• Anticoagulation UK</li> <li>• AOFAC Foundation</li> <li>• Arthritis Action</li> <li>• Arthritis and Musculoskeletal Alliance</li> <li>• Black Health Agency for Equality</li> <li>• British Sjögren's Syndrome Association</li> <li>• Genetic Alliance UK</li> <li>• Kidney Alliance</li> <li>• Kidney Care UK</li> <li>• Lupus Trust</li> <li>• Lupus UK</li> <li>• National Kidney Federation</li> <li>• National Rheumatoid Arthritis Society</li> <li>• Pain Concern</li> <li>• Pain UK</li> <li>• Scleroderma and Raynaud's UK</li> <li>• South Asian Health Foundation</li> <li>• Specialised Healthcare Alliance</li> <li>• Thrombosis UK</li> <li>• Versus Arthritis</li> </ul> <p><u>Professional groups</u></p> <ul style="list-style-type: none"> <li>• Association of British Neurologists</li> <li>• Association of Genetic Nurses &amp; Counsellors</li> <li>• Association of Renal Industries</li> <li>• Association of Renal Technologists</li> <li>• British Association for Surgery of the Knee</li> <li>• British Dermatological Nursing Group</li> <li>• British Geriatrics Society</li> </ul>	<p><u>General</u></p> <ul style="list-style-type: none"> <li>• All Wales Therapeutics and Toxicology Centre</li> <li>• Allied Health Professionals Federation</li> <li>• Board of Community Health Councils in Wales</li> <li>• British National Formulary</li> <li>• Care Quality Commission</li> <li>• Cell and Gene Therapy Catapult</li> <li>• Department of Health, Social Services and Public Safety for Northern Ireland</li> <li>• Healthcare Improvement Scotland</li> <li>• Medicines and Healthcare products Regulatory Agency</li> <li>• National Association of Primary Care</li> <li>• National Pharmacy Association</li> <li>• NHS Alliance</li> <li>• NHS Confederation</li> <li>• NHS England Specialised Rheumatology Clinical Reference Group</li> <li>• Scottish Medicines Consortium</li> <li>• Welsh Health Specialised Services Committee</li> <li>• Welsh Kidney Patients Association</li> </ul> <p><u>Comparator companies</u></p> <ul style="list-style-type: none"> <li>• Accord Healthcare (hydroxychloroquine, methotrexate, mycophenolate mofetil, prednisolone)</li> <li>• ADVANZ Pharma (methotrexate, prednisolone)</li> <li>• Aspen (azathioprine)</li> <li>• Baxter Healthcare (cyclophosphamide)</li> <li>• Blackrock Pharmaceuticals (hydroxychloroquine)</li> </ul>

Final stakeholder list for the single technology appraisal of anifrolumab for treating active autoantibody-positive systemic lupus erythematosus [ID3804]

Issue date: June 2021

Consultees	Commentators (no right to submit or appeal)
<ul style="list-style-type: none"> <li>• British Institute of Musculoskeletal Medicine</li> <li>• British Isles Lupus Assessment Group</li> <li>• British Myology Society</li> <li>• British Orthopaedic Association</li> <li>• British Orthopaedic Foot and Ankle Society</li> <li>• British Pain Society</li> <li>• British Renal Society</li> <li>• British Skin Foundation</li> <li>• British Society for Allergy and Clinical Immunology</li> <li>• British Society for Gene and Cell Therapy</li> <li>• British Society for Genetic Medicine</li> <li>• British Society for Haematology</li> <li>• British Society of Haemostasis and Thrombosis</li> <li>• British Society for Human Genetics</li> <li>• British Society for Rheumatology</li> <li>• British Society of Rehabilitation Medicine</li> <li>• British Thoracic Society</li> <li>• Clinical Leaders of Thrombosis</li> <li>• Physiotherapy Pain Association</li> <li>• Primary Care Dermatology Society</li> <li>• Primary Care Rheumatology and Musculoskeletal Medicine Society</li> <li>• Renal Association</li> <li>• Royal College of General Practitioners</li> <li>• Royal College of Nursing</li> <li>• Royal College of Pathologists</li> <li>• Royal College of Physicians</li> <li>• Royal Pharmaceutical Society</li> <li>• Royal Society of Medicine</li> <li>• Society for Endocrinology</li> <li>• Society for Vascular Technology</li> <li>• Society for Vascular Ultrasound</li> <li>• Society of Vascular Nurses</li> <li>• The Vascular Society of Great Britain and Ireland</li> <li>• UK Clinical Pharmacy Association</li> <li>• UK Primary Immunodeficiency Network</li> <li>• UK Renal Pharmacy Group</li> <li>• Urology Foundation</li> </ul>	<ul style="list-style-type: none"> <li>• Bristol Laboratories (hydroxychloroquine)</li> <li>• Cipla EU (methotrexate)</li> <li>• GlaxoSmithKline (belimumab)</li> <li>• Hospira UK (methotrexate)</li> <li>• Ipca Laboratories (hydroxychloroquine)</li> <li>• Logixx Pharma Solutions (prednisolone)</li> <li>• Medac GmbH (methotrexate)</li> <li>• Morningside Healthcare (methotrexate)</li> <li>• Mylan (azathioprine)</li> <li>• Napp Pharmaceuticals (rituximab)</li> <li>• Nordic Pharma (methotrexate)</li> <li>• Orion Pharma (methotrexate)</li> <li>• Pfizer (methotrexate, rituximab)</li> <li>• Phoenix Labs (prednisolone)</li> <li>• Roche Pharmaceuticals (mycophenolate mofetil, rituximab)</li> <li>• Sandoz GmbH (cyclophosphamide, rituximab)</li> <li>• Teva Pharma (mycophenolate mofetil)</li> <li>• Tillomed Laboratories (azathioprine, mycophenolate mofetil)</li> <li>• Wockhardt UK (prednisolone)</li> <li>• Zentiva (hydroxychloroquine, prednisolone)</li> </ul> <p><u>Relevant research groups</u></p> <ul style="list-style-type: none"> <li>• Bone Research Society</li> <li>• British Epidermo-Epidemiology Society</li> <li>• British Society for Immunology</li> <li>• Centre of Evidence-Based Dermatology, University of Nottingham</li> <li>• Chronic Pain Policy Coalition</li> <li>• Cochrane Cystic Fibrosis &amp; Genetic Disorders Group</li> <li>• Cochrane Musculoskeletal Group</li> <li>• Cochrane Skin Group</li> <li>• Cochrane Vascular</li> <li>• Genomics England</li> <li>• Kidney Research UK</li> <li>• MRC Clinical Trials Unit</li> <li>• National Institute for Health Research</li> <li>• Orthopaedic Research UK</li> <li>• Pain Relief Foundation</li> <li>• Skin Treatment and Research Trust</li> </ul>

Final stakeholder list for the single technology appraisal of anifrolumab for treating active autoantibody-positive systemic lupus erythematosus [ID3804]

Issue date: June 2021

Consultees	Commentators (no right to submit or appeal)
<u>Others</u> <ul style="list-style-type: none"> <li>• Department of Health and Social Care</li> <li>• NHS England</li> <li>• NHS Lincolnshire West CCG</li> <li>• NHS Mansfield and Ashfield CCG</li> <li>• Welsh Government</li> </ul>	<ul style="list-style-type: none"> <li>• Thrombosis Research Institute</li> </ul> <u>Associated Public Health groups</u> <ul style="list-style-type: none"> <li>• Public Health England</li> <li>• Public Health Wales</li> </ul>

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations from the stakeholder list, and which organisations we should include that have a particular focus on relevant equality issues.

### Consultees

Organisations that accept an invitation to participate in the appraisal; the company that markets the technology; national professional organisations; national patient organisations; the Department of Health and Social Care and the Welsh Government and relevant NHS organisations in England.

The company that markets the technology is invited to make an evidence submission, respond to consultations, nominate clinical specialists and has the right to appeal against the Final Appraisal Document (FAD).

All non-company consultees are invited to submit a statement<sup>1</sup>, respond to consultations, nominate clinical specialists or patient experts and have the right to appeal against the Final Appraisal Document (FAD).

### Commentators

Organisations that engage in the appraisal process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FAD for information only, without right of appeal. These organisations are: companies that market comparator technologies; Healthcare Improvement Scotland; other related research groups where appropriate (for example, the Medical Research Council [MRC], National Cancer Research Institute); other groups (for example, the NHS Confederation, NHS Alliance, and the British National Formulary).

<sup>1</sup> Non-company consultees are invited to submit statements relevant to the group they are representing.

All non-company commentators are invited to nominate clinical specialists or patient experts.